Comparative Pharmacology
Head-to-head clinical analysis: DARANIDE versus DORZOLAMIDE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARANIDE versus DORZOLAMIDE HYDROCHLORIDE.
DARANIDE vs DORZOLAMIDE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.
Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.
50 mg orally once or twice daily; maximum 100 mg/day.
One drop of 2% solution in the affected eye(s) three times daily.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours (prolonged in renal impairment). Clinical context: Short half-life necessitates multiple daily dosing for sustained diuretic effect.
Terminal elimination half-life is approximately 4 months for red blood cell carbonic anhydrase II binding; systemic half-life of free drug is about 3-4 hours.
Renal: unchanged drug (approximately 50% of absorbed dose) and metabolites. Biliary/fecal: minimal.
Renal: approximately 70% of a topically applied dose is excreted unchanged in urine over 120 hours; <2% fecal.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor